Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System

Voog, Éric; Bienvenu, Jacques; Warzocha, Krzysztof; Moullet, Isabelle; Dumontet, Charles; Thiéblemont, Catherine; Monneret, Guillaume; Gutowski, Marie-Claude; Coiffier, Bertrand; Salles, Gilles

doi:10.1200/jco.2000.18.2.325

Cited by 62 publications

(48 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reasons for poor toleration of chemotherapy among elderly HL patients might be at least partly attributable to circulating tumour necrosis factor (TNF). High TNF-levels predict myelosuppression in patients with lymphoma (26). High levels of TNF are also seen in patients with HL (27).…”

Section: Discussionmentioning

confidence: 85%

Patients above Sixty Years Lymphoma Treated with a New Strategy of Age with Hodgkin's

et al. 2002

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 85%

Patients above Sixty Years Lymphoma Treated with a New Strategy of Age with Hodgkin's

et al. 2002

View full text Add to dashboard Cite

“…Studies reviewed in this article showed risk factors for CIN or leukopenia (Table 1), FN (Table 2), and RDI (Table 3) in patients with NHL [16][17][18][19][20][21][22], ESBC [22][23][24][25][26], and other malignancies [27][28][29]. In these studies, advanced age, female sex,…”

Section: Risk Factors For Cinmentioning

confidence: 87%

Risk Models for Predicting Chemotherapy-Induced Neutropenia

2005

View full text Add to dashboard Cite

Neutropenia and its complications, including febrile neutropenia, are major dose-limiting toxicities of systemic cancer chemotherapy. A number of studies have attempted to identify risk factors for neutropenia and its consequences to develop predictive models capable of identifying patients at greater risk for such complications and to guide more effective and costeffective applications of the colony-stimulating factors. A systematic review of the literature showed that age, performance status, nutritional status, chemotherapy dose intensity, and low baseline blood cell counts were associated with the risk of severe and febrile neutropenia or reduced chemotherapy dose intensity in multivariate analysis in two or more studies. Similarly, age, diagnosis of leukemia or lymphoma, high temperature or low blood pressure at admission, and i.v. site infection along with low blood cell counts and organ dysfunction were associated with serious medical complications of febrile neutropenia, including bacteremia and death. The available risk model studies, however, had several limitations, including retrospective analyses of small study populations lacking independent validation, frequent missing values, and differences in the predictive factors considered. To overcome the limitations of previous studies, efforts are under way to develop and validate risk models based on large prospective studies in representative populations of patients receiving systemic chemotherapy. The

show abstract

“…Possible explanations for this include the compromised marrow reserve present in most CLL patients when therapy is required or the excess plasma TNF-␣ levels noted in this disease, 36,37 both factors known to predispose to chemotherapy-induced cytopenias. 38 However, a preliminary report on low-grade NHL noted similar enhanced myelosuppression when these 2 agents were combined, suggesting a more complicated mechanism may exist that is currently not well understood. 39 It is notable, nonetheless, that this excess neutropenia during induction with the combination of rituximab and fludarabine did not predispose to an excess number of neutropenic fever episodes or life-threatening infections when compared either with the sequential arm in this trial or with the previous intergroup trial, which administered fludarabine alone.…”

Section: Discussionmentioning

confidence: 99%

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

Byrd

Peterson

Morrison

et al. 2002

Blood

523

284

View full text Add to dashboard Cite

Recent studies have suggested that rituximab has clinical activity and modulates antiapoptotic proteins associated with drug resistance in chronic lymphocytic leukemia (CLL). We performed a randomized phase 2 study to determine the efficacy, safety, and optimal administration schedule of rituximab with fludarabine in previously untreated CLL patients. Patients were randomized to receive either 6 monthly courses of fludarabine concurrently with rituximab followed 2 months later by 4 weekly doses of rituximab for consolidation therapy or sequential fludarabine alone followed 2 months later by rituximab consolidation therapy. A total

show abstract

Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System

Cited by 62 publications

References 21 publications

Patients above Sixty Years Lymphoma Treated with a New Strategy of Age with Hodgkin's

Patients above Sixty Years Lymphoma Treated with a New Strategy of Age with Hodgkin's

Risk Models for Predicting Chemotherapy-Induced Neutropenia

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

Contact Info

Product

Resources

About